Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis
Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis
复制标题
DOI：
10.1136/ard.55.2.122
复制
发表时间：
1996-02-01
影响因子：
27.4
通讯作者：
Jayson, MIV
中科院分区：
文献类型：
--
作者：
Herrick, AL;Illingworth, K;Jayson, MIV
目的-确定测量内皮损伤、凝血激活和血小板激活的不同标记物是否可以区分原发性雷诺现象 (PRP)、局限性皮肤和弥漫性系统性硬化症（IcSSc 和 dSSc）患者以及健康对照受试者。方法-在严格控制的条件下，从 19 名健康对照受试者、10 名 PRP 患者、17 名 IcSSc 患者和 9 名 dSSc 患者中抽取空腹血，用于测量如下：血管性血友病因子（VWF）和可溶性血栓调节蛋白作为内皮损伤/激活的标志物，血栓素（如血栓素B-2）和β-血栓球蛋白作为血小板活化的标志物，组织纤溶酶原激活物抗原、组织纤溶酶原激活物活性和纤溶酶原激活物抑制剂-1（PAI-1）作为纤溶标志物。结果-SSc患者中VWF显着增加，并且有血栓素和组织纤溶酶原激活剂抗原（除了VWF）也呈线性趋势，以区分不同亚组的患者雷诺现象。患者 dSSc 的值最高。 VWF 和血栓素的综合指数在所研究的四个组中显示出高度显着的趋势。结论-VWF 以及较小程度的血栓素和组织纤溶酶原激活剂抗原与雷诺现象患者的疾病严重程度相关。现在需要进行前瞻性研究来确定这些参数是否可以用作疾病进展的标志。
Objective-To determine whether measurement of different markers of endothelial damage, activation of coagulation, and platelet activation might differentiate between patients with primary Raynaud's phenomenon (PRP), limited cutaneous and diffuse systemic sclerosis (IcSSc and dSSc), and healthy control subjects.Methods-Under carefully controlled conditions, fasting blood was drawn from 19 healthy control subjects, 10 patients with PRP, 17 with IcSSc and nine with dSSc for measurement of the following: von Willebrand factor (VWF) and soluble thrombomodulin as markers of endothelial damage/activation, thromboxane (as thromboxane B-2) and beta-thromboglobulin as markers of platelet activation, and tissue plasminogen activator antigen, tissue plasminogen activator activity and plasminogen activator inhibitor-1 (PAI-1) as markers of fibrinolysis.Results-VWF was increased significantly in patients with SSc, and there was also a linear trend for thromboxane and tissue plasminogen activator antigen (in addition to VWF) to differentiate between different subgroups of patients Raynaud's phenomenon. Patients dSSc had the highest values. A combined index of VWF and thromboxane showed a highly significant trend across the four groups studied.Conclusion-VWF, and to a lesser extent thromboxane and tissue plasminogen activator antigen, are associated with disease severity in patients with Raynaud's phenomenon. Prospective studies are now required to establish if these parameters can be used as markers of disease progression.